Comera Life Sciences Holdings Inc.
| NASDAQ: CMRA | Healthcare / Biotechnology / USA |
| 0.0627 | -0.0023 | -3.54% | Vol 10.44K | 1Y Perf -95.61% |
| Nov 29th, 2023 13:16 DELAYED |
| BID | 0.00 | ASK | 0.00 | ||
| Open | 0.0667 | Previous Close | 0.0650 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | - | Analyst Rating | — — 0.00 | |
| Potential % | - | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | — - | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 1.53 | Earnings Rating | — | |
| Market Cap | 1.93M | Earnings Date | 9th Nov 2023 | |
| Alpha | -0.08 | Standard Deviation | 0.25 | |
| Beta | 1.71 |
Today's Price Range 0.06270.0667 | 52W Range 0.03002.17 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 8.33% | ||
| 1 Month | -79.57% | ||
| 3 Months | -87.25% | ||
| 6 Months | -88.60% | ||
| 1 Year | -95.61% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | - | |||
ROE last 12 Months | 506.23 | |||
ROA (5Y Avg) | - | |||
ROA last 12 Months | -351.49 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | - | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | - | |||
Assets Turnover | 0.10 | |||
Receivables Turnover | 1.90 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.90 | ||||
| - | ||||
| 79.11 | ||||
| - | ||||
| -3.80 | ||||
| -0.57 | ||||
| -8.78 | ||||
| -0.17 | ||||
| 28.70M | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.90 | ||||
| 1.30 | ||||
| - | ||||
| - | ||||
| -1 335.10 | ||||
| Leverage Ratio | -0.70 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 63.90 | ||||
| -3 114.00 | ||||
| -3 096.80 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 476.98K | ||||
| 0.02 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | - | -0.08 | - |
| Q04 2022 | - | -0.18 | - |
| Q03 2022 | - | -0.20 | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | - |
| Estimates Count | - |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 10.44K |
| Shares Outstanding | 30.74K |
| Shares Float | 11.13M |
| Trades Count | 7 |
| Dollar Volume | 668 |
| Avg. Volume | 164.74K |
| Avg. Weekly Volume | 162.78K |
| Avg. Monthly Volume | 172.38K |
| Avg. Quarterly Volume | 159.07K |
Comera Life Sciences Holdings Inc. (NASDAQ: CMRA) stock closed at 0.065 per share at the end of the most recent trading day (a -6.81% change compared to the prior day closing price) with a volume of 191.40K shares and market capitalization of 1.93M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 0 people. Comera Life Sciences Holdings Inc. CEO is Jeffrey S. Hackman.
The one-year performance of Comera Life Sciences Holdings Inc. stock is -95.61%, while year-to-date (YTD) performance is -94.72%. CMRA stock has a five-year performance of %. Its 52-week range is between 0.03 and 2.17, which gives CMRA stock a 52-week price range ratio of 1.53%
Comera Life Sciences Holdings Inc. currently has a PE ratio of -0.90, a price-to-book (PB) ratio of -, a price-to-sale (PS) ratio of 79.11, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -351.49%, a ROC of -% and a ROE of 506.23%. The company’s profit margin is -%, its EBITDA margin is -3 096.80%, and its revenue ttm is $476.98 Thousand , which makes it $0.02 revenue per share.
Of the last four earnings reports from Comera Life Sciences Holdings Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Comera Life Sciences Holdings Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Comera Life Sciences Holdings Inc. is — (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for Comera Life Sciences Holdings Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Comera Life Sciences Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Comera Life Sciences Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 41.83, ATR14 : 0.04, CCI20 : -92.20, Chaikin Money Flow : -0.11, MACD : -0.07, Money Flow Index : 58.96, ROC : -81.43, RSI : 28.30, STOCH (14,3) : 10.15, STOCH RSI : 0.94, UO : 26.94, Williams %R : -89.85), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Comera Life Sciences Holdings Inc. in the last 12-months were: Barbara K. Finck (Buy at a value of $8 310), Edward Sullivan (Buy at a value of $13 504), Jim Sherblom (Buy at a value of $99 730), Kirsten Flowers (Buy at a value of $16 621), Roopom Banerjee (Buy at a value of $24 932), Soane David (Buy at a value of $139 986), Stuart A. Randle (Buy at a value of $41 553)
Comera Life Sciences Holdings Inc.
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting a formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
CEO: Jeffrey S. Hackman
Telephone: +1 617 871-2101
Address: 12 Gill Street, Woburn 01801, MA, US
Number of employees: 0
